Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Protection of Mice Against Syngeneic Lymphomata

II. Collaboration Between Drugs and Antibodies

Abstract

Rabbit anti-mouse tumour cell serum can be made tumour specific by absorption with normal mouse cells and in an in vivo protection test can be shown to have a measurable protective effect on mice against a given number of lethal doses of a lymphoma. Some drugs have been evaluated in this system. When drug treatment is combined with antibody treatment much greater protection can be obtained than when the same amounts of drug or antibody are used alone. It is preferable to administer drug before antibody and with the combined schedule it is possible in the test model to protect all mice from tumour growth, even allowing the tumour up to 48 h “get-away” time before starting treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, D., Buckham, S. & Manstone, A. Protection of Mice Against Syngeneic Lymphomata. Br J Cancer 30, 305–311 (1974). https://doi.org/10.1038/bjc.1974.197

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1974.197

This article is cited by

Search

Quick links